

pCODR Patient Advocacy Group Conflict of Interest Declarations

Name of registered patient advocacy group:	British Columbia Lung Association
Name of drug and indication under review:	Keytruda (Generic name – Pembrolizumab); Indication – Non-Small Cell Lung Cancer
Conflict of Interest Declarations	
To maintain the objectivity and credibility of the review process must disclose any conflicts of interpotential conflicts of interest that may influence information submitted. Conflict of interest declar negate or preclude the use of the patient advoca	erest. Patient advocacy groups must declare any e or have the appearance of influencing the aration is requested for transparency — it does not
Examples of conflicts of interest include, but are	e not limited to:
honoraria, gifts, and salary;	al industry e.g., educational or research grants, ationships with drug manufacturers or other interest
	y payments over the previous two years from any ct or indirect interest in the drug under review?
X No	
If no, please go to Section B	
Section B: Holdings or Other Interests	
Has this patient advocacy group received or is it \$10,000 (excluding mutual funds) for organizatio the drug under review? If yes, please list in the t	ns that may have a direct or indirect interest in
No	

Section C: Affiliations, personal or commercial relationships

Does this patient advocacy group have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries,

below.		
N/A		

affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table

I hereby certify that I have authority to disclose all relevant information with respect to any matter involving this patient advocacy group with a company, organization or entity that may place this patient advocacy group in a real, potential or perceived conflict of interest situation.

Signature: KAM

Date: 2017/20/01 Name: Kelly Ablog Morrant

pCODR Patient Advocacy Group Conflict of Interest Declarations

I	Name (of registered pat	tient	advocacy group:	Lung Cancer Canada
I	Name (of drug and indic	catio	on under review:	Pembrolizumab indicated for metastatic non-small cell lung carcinoma (NSCLC) whose tumours express PDL-1 (as determined by a validated test, after 1 st line chemotherapy
Cc	onflic	t of Interest	Dec	clarations	
rev poinf	view pr tential ormati	rocess must disclo conflicts of inter on submitted. Co	ose a rest onflic	any conflicts of inte that may influence	pCODR process, all participants in the pCODR rest. Patient advocacy groups must declare any or have the appearance of influencing the ration is requested for transparency — it does not cy group input.
Exa	amples	of conflicts of ir	ntere	est include, but are	not limited to:
	h	onoraria, gifts, a	nd sa	alary;	al industry e.g., educational or research grants, lationships with drug manufacturers or other
	b)	Section A: Payme	ent F	Received	
1.					payments over the previous two years from any t or indirect interest in the drug under review?
		Yes			
	lf no	, please go to Se	ction	ı B	
2					acy group receive? (Check all that apply.)
		Operating Funds		Program Funding (website)	
		Royalties		Research/education	onal grants
		Gifts	Χ	Sponsorship of Eve	ents
		Honoraria		Other, please spec	eify:

3.	Please provide th the box below.	e names of companies and org	ganizations and the	amounts of the paymen	ts in
	2016 Strat 2016	tegic Planning Workshop Evening of Hope			
	2016	Programs		<u></u>	
	2015 2015	Program Evening of Hope			
	c) Section B: H	Holdings or Other Interests			
		cacy group received or is it in nutual funds) for organizations			
		w? If yes, please list in the tab		nect of indirect interest	111
ſ	No				
L					
Sec	ction C: Affiliation	ns, personal or commercial rel	lationshins		
		•	•		
hea	alth technology ma	rocacy group have personal or anufacturer (including such ma ted corporations) or other into	anufacturer's parer	nt corporation, subsidiari	es,
of		d organizations and outline the			
De	iow.				
ı	No				
L					
ma	tter involving this	I have authority to disclose all patient advocacy group with	a company, organiz	ation or entity that may	
pla	ice this patient ad	vocacy group in a real, potent	ial or perceived co	nflict of interest situatio	n.
D	ato: January 2	Name: Shem Singh		. /	
	ate: January 3,)17	wame. snem smyn		At	

Signature:

pCODR Patient Advocacy Group Input on a Drug Review ©2017 pCODR | PAN-CANADIAN ONCOLOGY DRUG REVIEW

pCODR Patient Advocacy Group Conflict of Interest Declarations

Name of registered patient advocacy group:		nt advocacy group:	The Lung Association - Ontario	
Nam	ne of drug and indica	tion under review:	Keytruda (Generic name – Pembrolizumab); Indication – Non-Small Cell Lung Carcinoma	
Conf	flict of Interest	Declarations		
reviev poten inforn	v process must disclos tial conflicts of intere	se any conflicts of into est that may influence iflict of interest decla	e pCODR process, all participants in the pCODR erest. Patient advocacy groups must declare any e or have the appearance of influencing the aration is requested for transparency — it does not acy group input.	
Examp	oles of conflicts of inte	erest include, but are	e not limited to:	
•	honoraria, gifts, and	d salary; nal or commercial rel	al industry e.g., educational or research grants, ationships with drug manufacturers or other interest	
CC			y payments over the previous two years from any ct or indirect interest in the drug under review?	
lf	no, please go to Sect	ion B		
	Operating Funds Royalties Gifts	did this patient advoc Program Funding website) X Research/education Sponsorship of Events Other, please special	onal grants ents	
	ease provide the name e box below.	es of companies and o	organizations and the amounts of the payments in	
	Merck Canada Inc.	Cdn. \$		

Section B: Holdings or Other Interests

Has this patient advocacy group received or is it in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

Yes, 600 shares of Merck & Co. Inc valued at US\$	(as of November 30, 2016)

Section C: Affiliations, personal or commercial relationships

Does this patient advocacy group have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below.

N/A	

I hereby certify that I have authority to disclose all relevant information with respect to any matter involving this patient advocacy group with a company, organization or entity that may place this patient advocacy group in a real, potential or perceived conflict of interest situation.

Date: 2017/01/03 Name: Andrea Stevens Lavigne Signature: